Annovis Bio Inc. ANVS Archives - Page 4 of 4

FridayJul 19, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease

The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson’s Disease patients Following the announcement of these positive results, the company’s stock price surged by 76% The data revealed that while 12% of Parkinson’s Disease patients showed cognitive decline, buntanetap not only halted this decline but also led to improvements Annovis held a webcast to go over the results in more depth, which is available for replay on the company’s website Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s…

WednesdayJul 17, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap

Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023 The company's research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of neurodegenerative diseases Annovis continues to expand its position in an ongoing fight against neurodegenerative diseases Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, is…

TuesdayJul 16, 2024 1:05 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food and Drug Administration (“FDA”) to transition to a new solid form of buntanetap in future clinical trials. “In June 2024, Annovis announced the filing of a composition of matter patent for the new crystal form of buntanetap and a provisional patent for the manufacturing process of this new form,” the announcement reads. “The company conducted comprehensive bridge studies in various solvents and in animals, comparing the old…

FridayJun 28, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for the Treatment of Alzheimer’s Disease

Buntanetap is designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43 The study demonstrated significant efficacy and safety for buntanetap in a subgroup of early Alzheimer’s patients in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a recognized genetic factor linked to Alzheimer's Annovis Bio has been selected to present detailed data from its Alzheimer’s study at the Alzheimer’s Association International Conference(R) 2024 June is Alzheimer's & Brain Awareness Month, a time dedicated to raising awareness about Alzheimer's disease and other forms of dementia, as well as the importance of…

ThursdayJun 27, 2024 9:35 am

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Provisional Patent Covering Manufacturing Process of New Solid Forms of Buntanetap

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), is announcing the filing of a provisional patent. This patent covers the manufacturing process of new solid forms of buntanetap (formerly known as Posiphen or ANVS401), which targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins. According to the announcement, the patent encompasses the methods for manufacturing the new crystalline form of buntanetap (CAS# 3032752-92-1) as well as the entire synthesis process, from basic starting materials to finished (>99.9% pure) GMP product, suitable for manufacturing scale at ton…

TuesdayJun 18, 2024 12:44 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), will be presenting results from its latest Alzheimer’s study at the Alzheimer’s Association International Conference(R) 2024 (“AAIC”). The conference is slated to run from July 28–Aug. 1, 2024, in Philadelphia as well as online. According to the announcement, Annovis Bio senior VP of research & development Dr. Cheng Fang will present an extended 45-minute session at the conference; the presentation is scheduled to begin at 8 a.m. on July 31. He will be joined by Kathleen A. Welsh-Bohmer, PhD,…

TuesdayJun 11, 2024 1:37 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug-platform company developing novel therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting the results of its recent phase 2/3 Alzheimer’s study. The study was designed to evaluate Buntanetap, the company’s lead drug candidate. According to the report, key findings indicate that Buntanetap showed statistically significant efficacy and safety in the treatment of both carriers and noncarriers of Apolipoprotein E4 (APOE4), a genetic cause of AD. The company has scheduled an investor call for today at 4:30 p.m. ET to provide more detailed information and outline future development plans…

MondayJun 10, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Is ‘One to Watch’

Recent Achievements Annovis Bio recently announced statistically significant data from its Phase II/III Alzheimer’s study, showcasing Buntanetap’s potential to improve cognition in patients with mild AD Annovis Bio recently announced last patient last visit in the Phase III study of Buntanetap in patients with early Parkinson’s disease and expects data announcement in June 2024, marking significant progress in expanding its therapeutic reach The company has solidified strategic partnerships to enhance its research capabilities and broaden its market reach Investment Considerations Unique Market Position: Annovis Bio is the only company developing a drug for both AD and PD that inhibits multiple neurotoxic…

Site Search

Company Search

Tag: Annovis Bio Inc. ANVS